The primary objective is to assess the proportion of Non-valvular atrial fibrillation (NVAF) patients receiving the standard dose of 20 mg of rivaroxaban or the reduced dose of 15 mg of rivaroxaban.
The secondary objective is to determine if dosing patterns for rivaroxaban may be influenced by baseline chronic kidney disease (CKD) status (as a proxy for measured baseline renal function).
- Rivaroxaban (Xarelto, BAY59-7939) Drug
Intervention Desc: As prescribed by treating physicians ARM 1: Kind: Experimental Label: NVAF patients receiving 20 mg rivaroxaban Description: NVAF patients who receive a standard dose of rivaroxaban (20 mg daily) ARM 2: Kind: Experimental Label: NVAF patients receiving 15 mg rivaroxaban Description: NVAF patients who receive a reduced dose of rivaroxaban (15 mg daily)
Patients with non-valvular atrial fibrillation (NVAF)
|Type||Measure||Time Frame||Safety Issue|
|Primary||Number of NVAF patients receiving 20 mg Rivaroxaban||At baseline|
|Primary||Number of NVAF patients receiving 15 mg Rivaroxaban||At baseline|
|Secondary||Baseline renal function||At baseline|